(Q34167798)

English

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study (English)

1 reference

Europe PubMed Central

31 July 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

R Ratner

1

1 reference

Europe PubMed Central

31 July 2017

M Nauck

2

1 reference

Europe PubMed Central

31 July 2017

C Kapitza

3

1 reference

Europe PubMed Central

31 July 2017

V Asnaghi

4

1 reference

Europe PubMed Central

31 July 2017

M Boldrin

5

1 reference

Europe PubMed Central

31 July 2017

R Balena

6

1 reference

Europe PubMed Central

31 July 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

31 July 2017

Diabetic Medicine

1 reference

Europe PubMed Central

31 July 2017

27

1 reference

Europe PubMed Central

31 July 2017

5

1 reference

Europe PubMed Central

31 July 2017

556-562

1 reference

Europe PubMed Central

31 July 2017

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Biologic actions and therapeutic potential of the proglucagon-derived peptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2948428

5 July 2018

Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02990.X

21 January 2018

Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02990.X

21 January 2018

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02990.X

21 January 2018

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02990.X

21 January 2018

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20536952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1464-5491.2010.02990.X

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34167798&oldid=1645647606"